A new trade architecture just went live. The second wave is still coming.
BMY Reports July 30. The Patent Cliff Has a Counter-Argument.
Growth drugs now make up more than half of BMY's revenue. The market hasn't fully priced that.
A new trade architecture just went live. The second wave is still coming.
Growth drugs now make up more than half of BMY's revenue. The market hasn't fully priced that.